Omeprazole Capsule Multiple Dose/Steady State BE Requirement [Design Issues]

posted by Relaxation  – Germany, 2017-12-07 16:50 (2713 d 10:09 ago) – Posting: # 18041
Views: 3,482

Hello everybody.

Just a short input as I do not fully agree with the answer.

❝ Normally, Single dose fasting and fed studies are required.

Would be my answer, too.

❝ Reason may be, omeprazole has time-dependent kinetics (omeprazole auto-inhibits its metabolism). ❝ Hence, according to Guidance on the investigation of Bioavailability and Bioequivalence, a

❝ steady state study is required due to this time dependency.


Would it be possible to point to the guideline you are referring and maybe the page? I mean, I could follow that argument if the task was to clarify the pharmacokinetics of a product.
But in case of bioequivalence I fail to understand the need for a study at steady-state (and also fail to find that requirement in the guidelines I am aware of).

OK, if this was a prolonged release formulation, but, um, do such formulations for omeprazole exist :confused:.

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,668 registered users;
107 visitors (0 registered, 107 guests [including 64 identified bots]).
Forum time: 04:00 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5